Hoff, F. W., Banerjee, R., Khan, A. M., McCaughan, G., Wang, B., Wang, X., . . . Kaur, G. (2024). Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma. Blood Cancer Journal, 14(1), 1-8. https://doi.org/10.1038/s41408-024-01034-6
Chicago-referens (17:e uppl.)Hoff, Fieke W., et al. "Once-weekly Versus Twice-weekly Bortezomib in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal 14, no. 1 (2024): 1-8. https://doi.org/10.1038/s41408-024-01034-6.
MLA-referens (9:e uppl.)Hoff, Fieke W., et al. "Once-weekly Versus Twice-weekly Bortezomib in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal, vol. 14, no. 1, 2024, pp. 1-8, https://doi.org/10.1038/s41408-024-01034-6.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.